Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa

Simple item page
dc.contributor.authorTapia, M.D.
dc.contributor.authorArmah, G.
dc.contributor.authorBreiman, R.F.
dc.contributor.authorDallas, M.J.
dc.contributor.authorLewis, K.D.C.
dc.contributor.authorSow, S.O.
dc.contributor.authorRivers, S.B.
dc.contributor.authorLevine, M.M.
dc.contributor.authorLaserson, K.F.
dc.contributor.authorFeikin, D.R.
dc.contributor.authorVictor, J.C.
dc.contributor.authorCiarlet, M.
dc.contributor.authorNeuzil, K.M.
dc.contributor.authorSteele, A.D.
dc.date.accessioned2019-01-17T12:59:33Z
dc.date.available2019-01-17T12:59:33Z
dc.date.issued2012-04
dc.description.abstractThe efficacy of the pentavalent rotavirus vaccine (PRV), RotaTeq®, was evaluated in a double-blind, placebo-controlled, multicenter Phase III clinical trial conducted (April 2007-March 2009) in 3 low-income countries in Africa: Ghana, Kenya, and Mali. In total, 5468 infants were randomized 1:1 to receive 3 doses of PRV/placebo at approximately 6, 10, and 14 weeks of age; concomitant administration with routine EPI vaccines, including OPV, was allowed. HIV-infected infants were not excluded. The primary endpoint, vaccine efficacy (VE) against severe-rotavirus gastroenteritis (RVGE), as measured by Vesikari scoring system (VSS, score ≥11), from ≥14 days following Dose 3 through a follow-up period of nearly 2 years in the combined 3 African countries, and secondary endpoints by total follow-up period have been previously reported. In this study, we report post hoc subgroup analyses on secondary endpoints of public health importance. VE against RVGE of any severity was 49.2% (95%CI: 29.9, 63.5) through the first year of life and 30.5% (95%CI: 16.7, 42.2) through the complete follow-up period. VE against severe-gastroenteritis of any etiology was 21.5% (95%CI: <0, 38.4) through the first year of life and 10.6% (95%CI: <0, 24.9) through the complete follow-up period. Through the complete follow-up period, VE against severe-RVGE caused by (i) vaccine-contained G and P types (G1-G4, P1A[8]), (ii) non-vaccine G types (G8, G9, G10), and (iii) non-vaccine P types (P1B[4], P2A[6]) was 34.0% (95%CI:11.2, 51.2), 81.8% (95%CI:16.5, 98.0) and 40.7% (95%CI:8.4, 62.1), respectively. There was a trend towards higher VE with higher disease severity, although in some cases the numbers were small. In African countries with high under-5 mortality rates, PRV significantly reduced RVGE through nearly 2 years of follow-up; more modest reductions were observed against gastroenteritis of any etiology. PRV provides protection against severe-RVGE caused by diverse rotavirus genotypes, including those not contained in the vaccine. © 2012 Elsevier Ltd.en_US
dc.identifier.otherVolume 30, Supplement 1, Pages A79-A85
dc.identifier.otherhttps://doi.org/10.1016/j.vaccine.2012.01.022
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/26883
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectG genotypeen_US
dc.subjectGastroenteritisen_US
dc.subjectP genotypeen_US
dc.subjectRotavirusen_US
dc.subjectVaccine efficacyen_US
dc.titleSecondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.pdf
Size:
279.05 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Electron Microscopy Department